A Phase IIb double-blind trial has shown the success of the topical cream PAC‐14028 for the treatment of atopic dermatitis...
List view / Grid view
Filter the results
Phase 3 clinical program for upadacitinib in atopic dermatitis, the most common type of eczema, is planned to begin in the first half of 2018...
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the EC has granted marketing authorisation for Dupixent for use in adults with moderate-to-severe atopic dermatitis...
The US Food and Drug Administration (FDA) approved Sanofi and Regeneron's Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The European Medicines Agency (EMA) has accepted for review the marketing authorisation application for Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Regeneron Pharmaceuticals and Sanofi’s two placebo-controlled Phase 3 trials, evaluating dupixent (dupilumab) in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD), met their primary endpoints evaluating the extent and severity of the disease.
1 July 2016 | By Victoria White, Digital Content Producer
AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.
The Anacor acquisition adds crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, to Pfizer's pipeline...
6 June 2016 | By Victoria White, Digital Content Producer
Sanofi and Regeneron have announced that a one-year Phase III study evaluating investigational dupilumab met its primary and key secondary endpoints.
1 April 2016 | By Victoria White
Sanofi and Regeneron have announced positive topline results from two placebo-controlled Phase III studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD).
7 January 2016 | By Nicholas Jackson
DS Biopharma has announced positive top-line Phase IIa trial results for DS107 as an oral treatment for moderate to severe atopic dermatitis...
Black Swan Analysis has added to its Epiomic Epidemiology series of reports with Atopic Dermatitis forecast in 17 major markets 2015-2025
1 December 2015 | By Black Swan Analysis
Research and Markets has announced the addition of the "Epiomic Epidemiology Series: Atopic Dermatitis Forecast in 17 Major Markets 2015-2025" report to their offering...
19 November 2015 | By Victoria White
The global atopic dermatitis treatment market will more than double in value from $3.6 billion in 2014 to an estimated $7.3 billion by 2024, according to research and consulting firm GlobalData.
20 July 2015 | By Victoria White
Researchers have successfully treated patients with moderate to severe eczema using an arthritis drug recently shown to reverse two other skin conditions...